After Dai et al. described that taspine derivative 12k suppresses colorectal cancer cell growth by competitive targeting of ephrin-B2-related pathways, EPH/ephrin-expressing LC also arose as a feasible target of taspine anti-tumor treatment [56]. Here, EPHA1 is linked to neoplasm.